# EDGAR Filing Document

**Accession Number:** 0000882095
**File Stem:** 0000882095-26-000025
**Filing Date:** 2026-5
**Character Count:** 16413
**Document Hash:** eea69133fb963c3312dacf078f93dd5a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000882095-26-000025.hdr.sgml**: 20260507

**ACCESSION NUMBER**: 0000882095-26-000025

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 14

**REFERENCES 429**: 333-264713

**FILED AS OF DATE**: 20260507

**DATE AS OF CHANGE**: 20260507

**EFFECTIVENESS DATE**: 20260507

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GILEAD SCIENCES, INC.
- **CENTRAL INDEX KEY:** 0000882095
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 943047598
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-295661
- **FILM NUMBER:** 26954857

**BUSINESS ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404
- **BUSINESS PHONE:** 6505743000

**MAIL ADDRESS:**
- **STREET 1:** 333 LAKESIDE DR
- **CITY:** FOSTER CITY
- **STATE:** CA
- **ZIP:** 94404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GILEAD SCIENCES INC
- **DATE OF NAME CHANGE:** 19930328

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**As filed with the Securities and Exchange Commission on May 7, 2026**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON D.C. 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933**

   

**GILEAD SCIENCES, INC.**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **94-3047598** |
| (State or Other Jurisdiction of Incorporation or Organization) | (I.R.S. Employer Identification No.) |

---

**333 Lakeside Drive**

**Foster City, California 94404**

(Address of Principal Executive Offices, Zip Code)

**Gilead Sciences, Inc. 2022 Equity Incentive Plan**

(Full title of the plan)

**Keeley M. Cain Wettan**

**Executive Vice President, General Counsel, Legal and Compliance, and Secretary**

**333 Lakeside Drive**

**Foster City, California 94404**

**(650) 574-3000**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copy to:

**Ronald O. Mueller, Esq.<br>Gibson, Dunn & Crutcher LLP<br>1700 M Street, NW<br>Washington, DC 20036<br>(202) 955-8500**

   

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer", "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ⌧ | Accelerated filer | ◻ |
| Non-accelerated filer | ◻ | Smaller reporting company | ◻ |
| | | Emerging growth company | ◻ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 (this "Registration Statement") is filed by Gilead Sciences, Inc. (the "Registrant"), relating to the registration of 47,750,000 shares of the Registrant's common stock, par value $0.001 per share (the "Common Stock"), issuable to eligible persons under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, as amended and restated.

The contents of the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission (the "Commission") on May 5, 2022 (<u>[File No. 333-264713](https://www.sec.gov/Archives/edgar/data/882095/000110465922056468/tm2213709d1_s8.htm)</u>), together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8, and the Common Stock registered hereunder are in addition to the Common Stock registered on such registration statement.

**PART II<br>INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

---

| | |
|:---|:---|
| **Item 8.** | **Exhibits.** |

---

---

| | |
|:---|:---|
| **<u>Exhibit No.</u>** | **<u>Exhibit Description</u>** |
| <u>[4.1](https://www.sec.gov/Archives/edgar/data/882095/000088209524000016/ex322024restatedcertificat.htm)</u> | <u>[Restated Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant's Current Report on Form 8-K filed on May 9, 2024)](https://www.sec.gov/Archives/edgar/data/882095/000088209524000016/ex322024restatedcertificat.htm)[.](https://www.sec.gov/Archives/edgar/data/882095/000088209524000016/ex322024restatedcertificat.htm)</u> |
| <u>[4.2](https://www.sec.gov/Archives/edgar/data/882095/000088209525000022/gildex31amendedandrestated.htm)</u> | <u>[Amended and Restated Bylaws of the Registrant, as amended and restated on July 30, 2025 (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on August 4, 2025).](https://www.sec.gov/Archives/edgar/data/882095/000088209525000022/gildex31amendedandrestated.htm)</u> |
| <u>[5.1\*](gildex51opinionofgibsondun.htm)</u> | <u>[Opinion of Gibson, Dunn & Crutcher LLP.](gildex51opinionofgibsondun.htm)</u> |
| <u>[23.1\*](gildex51opinionofgibsondun.htm)</u> | <u>[Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).](gildex51opinionofgibsondun.htm)</u> |
| <u>[23.2\*](gildex232consentofindepend.htm)</u> | <u>[Consent of Independent Registered Public Accounting Firm](gildex232consentofindepend.htm)</u>. |
| <u>[24.1\*](#ibe826eaf96ce42e5b24d7db32635f2ee_126)</u> | <u>[Power of Attorney (included on the signature page of this Registration Statement).](#ibe826eaf96ce42e5b24d7db32635f2ee_126)</u> |
| <u>[99.1](https://www.sec.gov/Archives/edgar/data/882095/000088209526000008/gildex101equityincentivepl.htm)</u> | <u>[Gilead Sciences, Inc. 2022 Equity Incentive Plan, as amended and restated on April 30, 2026 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on May 4, 2026)](https://www.sec.gov/Archives/edgar/data/882095/000088209526000008/gildex101equityincentivepl.htm)</u>.  |
| <u>[107.1\*](exfilingfees.htm)</u> | <u>[Filing Fee Table.](exfilingfees.htm)</u> |

---

_______________________________

\* Filed herewith.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended (the "Securities Act"), the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foster City, State of California, on May 7, 2026.

---

| | |
|:---|:---|
| **GILEAD SCIENCES, INC.** | **GILEAD SCIENCES, INC.** |
| By: | /s/&nbsp;&nbsp;&nbsp;&nbsp;DANIEL P. O'DAY |
| Name: | Daniel P. O'Day |
| Title: | Chairman and Chief Executive Officer |

---

------

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Daniel P. O'Day, Keeley M. Cain Wettan and Andrew D. Dickinson, and each of them, as the individual's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;DANIEL P. O'DAY | Chairman and Chief Executive Officer | May 7, 2026 |
| Daniel P. O'Day | *(Principal Executive Officer)* |  |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;ANDREW D. DICKINSON | Chief Financial Officer | May 7, 2026 |
| Andrew D. Dickinson | *(Principal Financial Officer)* |  |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;ERIN E. BURKHART | Senior Vice President, Controllership and Chief Accounting Officer | May 7, 2026 |
| Erin E. Burkhart | *(Principal Accounting Officer)* |  |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;ANTHONY WELTERS | Lead Independent Director | May 7, 2026 |
| Anthony Welters |  |  |
| /s/ JACQUELINE K. BARTON | Director | May 7, 2026 |
| Jacqueline K. Barton, Ph.D. |  |  |
| /s/ JEFFREY A. BLUESTONE | Director | May 7, 2026 |
| Jeffrey A. Bluestone, Ph.D. |  |  |
| /s/ SANDRA J. HORNING | Director | May 7, 2026 |
| Sandra J. Horning, M.D. |  |  |
| /s/ KELLY A. KRAMER | Director | May 7, 2026 |
| Kelly A. Kramer |  |  |
| /s/ TED W. LOVE | Director | May 7, 2026 |
| Ted W. Love, M.D. |  |  |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;HARISH MANWANI | Director | May 7, 2026 |
| Harish Manwani |  |  |
| /s/&nbsp;&nbsp;&nbsp;&nbsp;JAVIER J. RODRIGUEZ | Director | May 7, 2026 |
| Javier J. Rodriguez |  |  |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? exfilingfees

**Exhibit 107.1**

**Calculation of Filing Fee Tables**

**FORM S-8**

(Form Type)

**GILEAD SCIENCES, INC.**

(Exact Name of Registrant as Specified in its Charter)

<u>Table 1: Newly Registered Securities</u> 

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount Registered** | **Proposed Maximum<br>Offering Price Per Unit** | **Maximum<br>Aggregate<br>Offering Price** | **Fee Rate** | **Amount of<br>Registration Fee** |
| Equity<sup>(1)</sup> | Common stock, par value $0.001 per share | Rule 457(a) | 47750000 | $130.09 | $6211797500.00 | $138.10 per $1,000,000 | $857849.23 |
| **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $6211797500.00 |  | $857849.23 |
| **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  |  |
| **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $857849.23 |

---

(1)&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 shall also cover such indeterminate number of additional shares of common stock, par value $0.001 per share, of the Registrant (the "Common Stock") as may become issuable to prevent dilution in the event of stock splits, stock dividends or similar transactions pursuant to the terms of the Gilead Sciences, Inc. 2022 Equity Incentive Plan, as amended and restated (the "Plan"). The "Proposed Maximum Offering Price Per Unit" and the "Maximum Aggregate Offering Price" are estimated solely for the purpose of calculating the registration fee pursuant to Rules 457(c) and (h) under the Securities Act, and based on the average of the high and low sale prices of the Common Stock, as quoted on The Nasdaq Global Select Market, on April 30, 2026. The "Amount Registered" represents an additional 47,750,000 shares of Common Stock reserved for issuance under the Plan.

## Exhibit 5.1

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Exhibit 5.1**

![image_0a.jpg](image_0a.jpg)

May 7, 2026

Gilead Sciences, Inc.333 Lakeside DriveFoster City, California 94404

Re:&nbsp;&nbsp;&nbsp;&nbsp;Registration Statement on Form S-8

Ladies and Gentlemen:&nbsp;&nbsp;&nbsp;&nbsp;

We have examined the Registration Statement on Form S-8 (the "<u>Registration Statement</u>") of Gilead Sciences, Inc., a Delaware corporation (the "<u>Company</u>"), filed with the Securities and Exchange Commission (the "<u>Commission</u>") pursuant to the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), in connection with the offering by the Company of up to 47,750,000 shares of the Company's common stock, par value $0.001 per share (the "<u>Common Stock</u>"), issuable to eligible persons under the Gilead Sciences, Inc. 2022 Equity Incentive Plan, as amended and restated (the "<u>Plan</u>").

We have examined the Plan and the originals, or photostatic or certified copies, of such records of the Company and certificates of officers of the Company and of public officials and such other documents as we have deemed relevant and necessary as the basis for the opinions set forth below. We have also made such other investigations as we have deemed relevant and necessary or appropriate in connection with the opinion hereinafter set forth. In our examination, we have assumed the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plan that would expand, modify or otherwise affect the terms of the Plan or the respective rights or obligations of the participants thereunder. Finally, we have assumed the accuracy of all other information provided to us by the Company during the course of our investigations, on which we have relied in issuing the opinion expressed below.

Based upon the foregoing examination and in reliance thereon, and subject to the assumptions stated and in reliance on statements of fact contained in the documents that we have examined, we are of the opinion that the shares of Common Stock issuable under the Plan, when issued and sold in accordance with the terms of the Plan and against payment therefor, and when the Registration Statement has become effective under the Securities Act, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "<u>DGCL</u>"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

Very truly yours,

/s/ Gibson, Dunn & Crutcher

GIBSON, DUNN & CRUTCHER

**<br>Gibson, Dunn & Crutcher LLP**<br>1700 M Street, N.W. \| Washington, D.C. 20036-4504 \| T: 202.955.8500 \| F: 202.467.0539 \| gibsondunn.com<br>

## Exhibit 23.2

**Exhibit 23.2** 

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Gilead Sciences, Inc. 2022 Equity Incentive Plan of our report dated February 24, 2026, with respect to the consolidated financial statements of Gilead Sciences, Inc. and the effectiveness of internal control over financial reporting of Gilead Sciences, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2025, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California

May 7, 2026

<br>